Core Viewpoint - Guichuang Tongqiao Medical Technology Co., Ltd. has received approval from the Hong Kong Stock Exchange to remove the "B" designation from its stock code, marking a significant milestone for the company as it transitions from being classified under the 18A listing rules for unprofitable biotech firms to meeting standard listing requirements [2][3] Group 1: Company Developments - The company plans to implement its first cash dividend post-listing, with a total cash dividend amounting to RMB 32.47 million (including tax) [2] - Guichuang Tongqiao was listed on the Hong Kong Stock Exchange in 2021 under the 18A rules and has since accelerated its product pipeline and commercialization efforts, achieving a revenue of RMB 780 million in 2024, a year-on-year increase of 48.3% [2] - The company has successfully achieved a net profit of over RMB 100 million for the first time in 2024, marking its first full-year profitability [2] Group 2: Product and Market Expansion - Guichuang Tongqiao has established a product pipeline of 66 items, with 47 products approved for sale in China, and its marketing network covers over 3,000 hospitals domestically [3] - The company has successfully won bids for key products in multiple rounds of provincial and national procurement in 2024, including the Tongqiao Silver Snake Intracranial Support Catheter and ZYLOXPenguin Iliac Vein Stent [3] - In terms of international expansion, Guichuang Tongqiao generated RMB 22.58 million in overseas revenue in 2024, with a compound annual growth rate of 87% over the past four years, and has commercialized 20 products in 24 countries and regions [3]